BMS-986158, a highly selective and potent inhibitor of BRD2/BRD4, has demonstrated anti-cancer activity through the downregulation of BRD4 and c-MYC expressions in preclinical efficacy studies and a clinical trial for patients with solid tumors (NCT02419417) (12, 13). Here, MYC is linked to cancer.